OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

trialsTrialPositive

RTOG 9402

RTOG 9402 looked negative at first and then, with long follow-up, showed that adding PCV chemotherapy to radiotherapy doubles survival in oligodendrogliomas with 1p/19q co-deletion, from about seven to fourteen years.